Dianthus Therapeutics, Inc. /DE/ Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Dianthus Therapeutics, Inc. /DE/ stock issued during period, value, new issues for the quarter ending 2026-03-31 was $58.73M.
- Dianthus Therapeutics, Inc. /DE/ stock issued during period, value, new issues for the quarter ending 2023-09-30 was $71.59M, a 2491.21% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ stock issued during period, value, new issues for the quarter ending 2022-12-31 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ stock issued during period, value, new issues for the quarter ending 2022-09-30 was $2.76M.
- Dianthus Therapeutics, Inc. /DE/ stock issued during period, value, new issues for fiscal 2024 was $39.20M, a 45.42% decline from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ stock issued during period, value, new issues for fiscal 2023 was $71.83M, a 2499.53% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ stock issued during period, value, new issues for fiscal 2022 was $2.76M, a 96.79% decline from fiscal 2021.
- Dianthus Therapeutics, Inc. /DE/ stock issued during period, value, new issues for fiscal 2021 was $86.10M, a 33.35% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $58.73M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $39.20M 10-K · filed 2026-03-09 | |
| 2023-12-31 | $71.83M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $71.59M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $2.76M 10-K · filed 2023-03-23 |
| 2022-09-30 | $2.76M 10-Q · filed 2022-11-03 | |
| 2021-12-31 | $86.10M 10-K · filed 2023-03-23 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $64.56M 10-K · filed 2022-03-08 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | |
| 2020-06-30 | $64.56M 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $60.28M 10-K · filed 2021-03-03 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | |
| 2019-06-30 | $60.28M 10-Q · filed 2020-08-06 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $89.91M 10-K · filed 2020-03-03 |
| 2018-06-30 | $90.03M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |